Illumina, Inc. (ILMN)

NASDAQ: ILMN · Real-Time Price · USD
97.32
-0.86 (-0.88%)
Sep 9, 2025, 11:52 AM - Market open
-0.88%
Market Cap14.96B
Revenue (ttm)4.28B
Net Income (ttm)1.26B
Shares Out 153.70M
EPS (ttm)7.91
PE Ratio12.31
Forward PE20.89
Dividendn/a
Ex-Dividend Daten/a
Volume238,582
Open98.42
Previous Close98.18
Day's Range97.03 - 98.48
52-Week Range68.70 - 156.66
Beta1.43
AnalystsBuy
Price Target123.67 (+27.08%)
Earnings DateNov 3, 2025

About ILMN

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]

Sector Healthcare
IPO Date Jul 28, 2000
Employees 10,370
Stock Exchange NASDAQ
Ticker Symbol ILMN
Full Company Profile

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Financial Statements

Analyst Summary

According to 15 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price target is $123.67, which is an increase of 27.08% from the latest price.

Price Target
$123.67
(27.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, custome...

Other symbols: LAB
6 days ago - PRNewsWire

mRNA Biotechs - Long-Term Value Risks Abound

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...

12 days ago - Seeking Alpha

Illumina: The Stock Is Still Undervalued

Illumina exceeded Q2FY25 expectations and raised FY25 guidance, driven by resilient Chinese operations and strong clinical market growth, especially in oncology. The company is expanding into proteomi...

5 weeks ago - Seeking Alpha

These Analysts Boost Their Forecasts On Illumina Following Upbeat Results

Illumina, Inc. ILMN reported better-than-expected earnings for the second quarter on Thursday.

5 weeks ago - Benzinga

Illumina, Inc. (ILMN) Q2 2025 Earnings Call Transcript

Illumina, Inc. (NASDAQ:ILMN) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Ankur Dhingra - Chief Financial Officer Brian Blanchett - VP of Finance & Treasurer and Int...

5 weeks ago - Seeking Alpha

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basis GAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025 GAAP diluted...

5 weeks ago - PRNewsWire

Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling

Illumina TruSight™ Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input Illumina's growing research and clinical...

5 weeks ago - PRNewsWire

Illumina Stock: What Went Wrong And Why It's Best To Stay Away

Illumina Inc. ILMN is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that go beyond ...

7 weeks ago - Benzinga

Illumina: Higher Profit Margin Despite GRAIL Divestiture And Macroeconomic Headwinds

With Illumina's divestiture of GRAIL, the company will improve its operating expenses, since GRAIL reported significant losses while it was part of Illumina. The global DNA sequencing market is expect...

2 months ago - Seeking Alpha

Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

SAN DIEGO , July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025....

2 months ago - PRNewsWire

Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year

Illumina was also recognized as one of the Best Companies to Work For byU.S. News & World Report SAN DIEGO , July 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced two awards recog...

2 months ago - PRNewsWire

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumin...

Other symbols: LAB
2 months ago - PRNewsWire

Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

BALTIMORE--(BUSINESS WIRE)--Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing r...

2 months ago - Business Wire

lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics

SAN DIEGO , June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) ...

3 months ago - PRNewsWire

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO , May 29, 2025 /PRNewswire/ -- Illumina ...

3 months ago - PRNewsWire

Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

Illumina, Inc. (NASDAQ:ILMN) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 2:30 PM ET Company Participants Jacob Thaysen - Chief Executive Officer Conference Call Participant...

3 months ago - Seeking Alpha

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see...

3 months ago - CNBC Television

Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies

Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illum...

3 months ago - PRNewsWire

Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel

FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, an...

4 months ago - Business Wire

Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%

Carl Icahn is making bold moves from the lab to the tarmac.

Other symbols: JBLU
4 months ago - Benzinga

Illumina To Webcast Upcoming Investor Conference

SAN DIEGO , May 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41st Annual Bernstein Strategic Decisi...

4 months ago - PRNewsWire

Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications

Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, ...

4 months ago - PRNewsWire

Illumina Analysts Lower Their Forecasts After Q1 Results

Illumina, Inc. ILMN reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday.

4 months ago - Benzinga

Illumina: Multiple Headwinds Point To Limited Upside In 2025

Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles, notably from China and competition from Roche's SBX technology. Q1 2025 results were in l...

4 months ago - Seeking Alpha

Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript

Illumina, Inc. (NASDAQ:ILMN) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Blanchett - Interim Head of Investor Relations Jacob Thaysen - Chief Executive Officer ...

4 months ago - Seeking Alpha